BHC
insider transactionsBausch Health Companies Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-44.1K
0 buy · 44.1K sell
Net value · 365d
-$247.8K
$0 in · $247.8K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
4
0 buy · 44.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
45.9K sh
Own +17%
-
Grant·A
Director
$0
45.9K sh
Own New
-
Grant·A
Director
$0
45.9K sh
Own +18%
-
Grant·A
Director
$0
45.9K sh
Own +12%
-
Grant·A
Director
$0
45.9K sh
Own +103%
-
Grant·A
Director
$0
45.9K sh
Own +93%
-
Grant·A
Director
$0
45.9K sh
Own +19%
-
Grant·A
Director
$0
45.9K sh
Own +152%
-
Grant·A
Director
$0
45.9K sh
Own +51%
-
Sell·S
Director · 10b5-1
$132.8K
24.5K sh · $5.43
Own -33%
-
Grant·A
Director
$32.1K
5.9K sh · $5.40
Own +15%
-
Grant·A
Director
$62.5K
11.6K sh · $5.40
Own +3%
-
Grant·A
Director
$6.9K
1.3K sh · $5.40
Own +0%
-
Sell·S
EVP, General Counsel · 10b5-1
$25.5K
4.4K sh · $5.77
Own -1%
-
Other·J
EVP, General Counsel · 10b5-1
$820.6K
137.9K sh · $5.95
-
Other·F
EVP, General Counsel · 10b5-1
$101.0K
17.0K sh · $5.95
Own -2%
-
Sell·S
EVP, General Counsel · 10b5-1
$39.6K
6.9K sh · $5.78
Own -1%
-
Other·J
Thomas Appio KEY
Chief Executive Officer
$6.8M
1.1M sh · $5.95
-
Other·F
Thomas Appio KEY
Chief Executive Officer
$498.0K
83.7K sh · $5.95
Own -2%
-
Other·F
EVP, CFO
$290.9K
49.1K sh · $5.93
Own -6%
-
Other·F
EVP, General Counsel · 10b5-1
$156.1K
26.3K sh · $5.93
Own -3%
-
Other·F
Thomas Appio KEY
Chief Executive Officer
$492.7K
83.1K sh · $5.93
Own -2%
-
Sell·S
EVP, General Counsel · 10b5-1
$49.9K
8.4K sh · $5.95
Own -1%
-
Other·F
EVP, US Pharma
$106.2K
17.6K sh · $6.04
Own -4%
-
Other·F
EVP, General Counsel · 10b5-1
$194.6K
32.2K sh · $6.04
Own -4%
-
Other·F
EVP, CFO
$217.3K
36.0K sh · $6.04
Own -5%
-
Other·F
Thomas Appio KEY
Chief Executive Officer
$703.7K
116.5K sh · $6.04
Own -3%
-
Grant·A
SVP, Controller & CAO
$0
45.9K sh
Own +168%
-
Grant·A
EVP, US Pharma
$0
157.1K sh
Own +60%
-
Grant·A
EVP, General Counsel · 10b5-1
$0
212.3K sh
Own +33%
-
Grant·A
EVP, CFO
$0
276.1K sh
Own +54%
-
Grant·A
Thomas Appio KEY
Chief Executive Officer
$0
815.4K sh
Own +28%
-
Grant·A
EVP, General Counsel
$0
137.9K sh
Own +28%
-
Grant·A
Thomas Appio KEY
Chief Executive Officer
$0
1.1M sh
Own +64%
-
Grant·A
Director
$0
9.0K sh
Own +3%
-
Grant·A
Director
$0
4.6K sh
Own +14%
-
Grant·A
Director
$0
989 sh
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | Amy B Wechsler | Grant A | 45.9K | $0 |
| May 22, 2026 | Eiry Roberts | Grant A | 45.9K | $0 |
| May 22, 2026 | Robert N Power | Grant A | 45.9K | $0 |
| May 22, 2026 | John Paulson | Grant A | 45.9K | $0 |
| May 22, 2026 | Sandra Leung | Grant A | 45.9K | $0 |
| May 22, 2026 | Frank D. Lee | Grant A | 45.9K | $0 |
| May 22, 2026 | Sarah B Kavanagh | Grant A | 45.9K | $0 |
| May 22, 2026 | Michael Goettler | Grant A | 45.9K | $0 |
| May 22, 2026 | Christian A Garcia | Grant A | 45.9K | $0 |
| May 19, 2026 | Frank D. Lee 10b5-1 | Sell S | 24.5K | $132.8K |
| Mar 31, 2026 | Sandra Leung | Grant A | 5.9K | $32.1K |
| Mar 31, 2026 | John Paulson | Grant A | 11.6K | $62.5K |
| Mar 31, 2026 | Amy B Wechsler | Grant A | 1.3K | $6.9K |
| Mar 3, 2026 | Seana Carson 10b5-1 | Sell S | 4.4K | $25.5K |
| Mar 2, 2026 | Seana Carson 10b5-1 | Other J | 137.9K | $820.6K |
| Mar 2, 2026 | Seana Carson 10b5-1 | Other F | 17.0K | $101.0K |
| Mar 2, 2026 | Seana Carson 10b5-1 | Sell S | 6.9K | $39.6K |
| Mar 2, 2026 | Thomas Appio KEY | Other J | 1.1M | $6.8M |
| Mar 2, 2026 | Thomas Appio KEY | Other F | 83.7K | $498.0K |
| Feb 27, 2026 | Jean-Jacques Charhon KEY | Other F | 49.1K | $290.9K |
| Feb 27, 2026 | Seana Carson 10b5-1 | Other F | 26.3K | $156.1K |
| Feb 27, 2026 | Thomas Appio KEY | Other F | 83.1K | $492.7K |
| Feb 27, 2026 | Seana Carson 10b5-1 | Sell S | 8.4K | $49.9K |
| Feb 26, 2026 | Aimee J. Lenar | Other F | 17.6K | $106.2K |
| Feb 26, 2026 | Seana Carson 10b5-1 | Other F | 32.2K | $194.6K |
| Feb 26, 2026 | Jean-Jacques Charhon KEY | Other F | 36.0K | $217.3K |
| Feb 26, 2026 | Thomas Appio KEY | Other F | 116.5K | $703.7K |
| Feb 25, 2026 | Steven Hyosig Lee | Grant A | 45.9K | $0 |
| Feb 25, 2026 | Aimee J. Lenar | Grant A | 157.1K | $0 |
| Feb 25, 2026 | Seana Carson 10b5-1 | Grant A | 212.3K | $0 |
| Feb 25, 2026 | Jean-Jacques Charhon KEY | Grant A | 276.1K | $0 |
| Feb 25, 2026 | Thomas Appio KEY | Grant A | 815.4K | $0 |
| Feb 9, 2026 | Seana Carson | Grant A | 137.9K | $0 |
| Feb 9, 2026 | Thomas Appio KEY | Grant A | 1.1M | $0 |
| Dec 31, 2025 | John Paulson | Grant A | 9.0K | $0 |
| Dec 31, 2025 | Sandra Leung | Grant A | 4.6K | $0 |
| Dec 31, 2025 | Amy B Wechsler | Grant A | 989 | $0 |
About BHC insider trading
This page tracks insider transactions for Bausch Health Companies Inc. (BHC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.